Dr. Jeffrey L. Cummings

Research Professor, Department of Brain Health
Director, Chambers-Grundy Center for Transformative Neuroscience at UNLV
Expertise: Neuroscience, neurodegenerative diseases, Alzheimer’s Disease, drug development, clinical trials, neurotherapeutics

Biography

Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.

Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society’s Henderson Award (2006), the national Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), and the American Association of Geriatric Psychiatry’s Distinguished Scientist Award (2010). 

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.

Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award (2017), the International Society of CNS Drug Development’s Leadership and Achievement Award and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award (2018).

Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and he is principal investigator/director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.

Education

  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

United Press International
Predicting when new drugs come to market in the United States has never been an exact science, and it has become even harder since the start of the COVID-19 pandemic, experts told UPI. But some drugs on the horizon have the potential to make a major impact.
Alzheimer's News Today
AB Science is initiating a Phase 3 trial to evaluate the safety and efficacy of its candidate therapy masitinib in patients with mild to moderate Alzheimer’s disease.
Neurology Live
Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1
Streetwise Reports
Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."

Articles Featuring Dr. Jeffrey L. Cummings

Dancers with the UNLV Ewalu Club
Campus News | October 4, 2022

A collection of news stories highlighting research wins, expert insights, and academic achievement.

people doing research
Research | December 27, 2021

UNLV researchers made international headlines this year with their discoveries. Here's a roundup of some of our top stories of 2021.

A man stocking shelfs at the food pantry
Campus News | December 8, 2021

A collection of news stories featuring research and accomplishment at UNLV.